Matthias J. Schnell, PhD
Philadelphia, PA 19107
(215) 503-5393 fax
Research and Clinical Interests
Research interests of the laboratory are the development of novel vaccines and viral pathogenesis.
Vaccines: Our laboratory develops Rhabdovirus-based vectors as vaccines against other infectious diseases. We are particularly interested in using molecular adjuvants and other molecules to enhance antigen-specific immunity and manipulate and retarget immune cells. Using different molecular approaches, we perform detailed studies of highly attenuated RVs expressing HIV-1 or SIV genes and analyze their immunogenicity in mice. Our most promising HIV vaccine candidates are currently being analyzed in a monkey model for AIDS. Other approaches include using genetically modified RV G proteins or RV capsids to carry antigens of other pathogens as vaccines against Anthrax and Botulism.
We also seek to develop safer and more potent RV vaccines for wildlife and humans.
Pathogenesis: We are interested in understanding the interaction of rabies with the infected host at the molecular level. The molecular mechanism of rabies virus pathogenesis is not well understood, and our research analyzes the different functions of the rhabdoviral proteins (e.g. rabies virus) and their interactions with host proteins and the immune system. Current projects are directed toward understanding:
- RV virus neurotropism and neuroinvasiveness: The transport of RV within neurons and the interaction of the RV phosphoprotein and glycoprotein with host proteins (receptors and transporter molecules)
- Immune responses of wild-type RV and RV-based vectors in the infected host (innate and adaptive)
Most Recent Peer-Reviewed Publications
- Ifit2 is a restriction factor in rabies virus pathogenicity
- Progress in Ebola Virus Vaccine Development
- Inactivated recombinant rabies viruses displaying canine distemper virus glycoproteins induce protective immunity against both pathogens
- The final (Oral Ebola) vaccine trial on captive chimpanzees?
- Toward an Effective Ebola Virus Vaccine
- One-Health: A safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies virus
- Keeping it in check: Chronic viral infection and antiviral immunity in the brain
- An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted with Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models
- Everything You Always Wanted to Know about Rabies Virus (But Were Afraid to Ask)
- Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against lethal zaire and Sudan ebolaviruses
- Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics
- Rhabdovirus-based vaccine platforms against henipaviruses
- Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine
- Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses
- Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs
- Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo
- Rabies virus replication and pathogenesis
- Small-molecule probes targeting the viral PPxY-host nedd4 interface block egress of a broad range of RNA viruses
- Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein
- Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV